Telix Pharmaceuticals (TLX) said late Wednesday the first patients with metastatic hormone-sensitive prostate cancer have been dosed with TLX597-Tx in a phase 2 trial at St Vincent's Hospital in Sydney, Australia.
The OPTIMAL-e trial will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA2 study which recently completed patient enrollment, the firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.